Cheaper eye drug could save sight for millions with diabetes

NCT ID NCT07663370

Completed Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines how well a biosimilar (a lower-cost copy) of the drug ranibizumab works for diabetic macular edema, a condition that causes vision loss in people with diabetes. Researchers will review medical records of 60 adults who received at least one injection of the biosimilar in routine care. They will measure changes in vision and retinal swelling to see if the biosimilar is a safe and effective option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ranibizumab biosimilar
What this could lead to: If effective, this could offer a more affordable treatment option for diabetic macular edema, potentially improving access to care.
What could go wrong: This is a small, retrospective study, so results may not apply to all patients. The biosimilar may not work as well as the original drug in some cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-VEGF TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-VEGF TREATMENT BIOSIMILAR RANIBIZUMAB

Contacts and locations

Locations

Benha University

Banhā, Benha, 13111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.